Clinical Trial Update: Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial is investigating venetoclax in combination with a fractionated busulfan conditioning regimen for high-risk acute myeloid leukemia, ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• BUSULFAN (Busulfan)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2, Phase 3 | Status: RECRUITING